Arcus Biosciences, Inc. RCUS 深 滬
等待開盤 06-25 09:30:00 美东时间
29.13
+0.950
+3.37%
華盛通- 最 高29.85
- 今 開28.42
- 成交量 84.95万股
- 最 低 28.28
- 昨 收 28.18
- 總市值 36.64亿
- 52周最高 29.85
- 市盈率 靜 --
- 換手率 0.68%
- 52周最低 8.03
- 委 比 81.82%
- 總股本 1.26亿
- 歷史最高 49.10
- 量 比 0.66
- 振 幅 5.57%
- 歷史最低 6.30
- 每 手 1
- 風險率 5.86%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Arcus Biosciences Enters Clinical Trial Collaboration And Supply Agreement With Bristol Myers Squibb; Will Supply Casdatifan, Its Investigational Small-Molecule HIF-2a Inhibitor
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune
06-03 20:11
美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级
今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元
05-19 10:55
Truist Securities Assumes Arcus Biosciences at Buy, Raises Price Target to $35
Truist Securities analyst Supawat Thongthip assumes Arcus Biosciences (NYSE:RCUS) with a Buy rating and raises Price Target to $35.
05-18 23:06
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
Arcus Biosciences shares are trading lower after the company reported worse-than-expected Q1 financial results.
Arcus Biosciences shares are trading lower after the company reported worse-tha...
05-06 05:08
Earnings Scheduled For May 5, 2026
Companies Reporting Before The Bell • Repligen (NASDAQ:RGEN) is projected to re...
05-05 19:12
What's Going On With Arcus Biosciences Stock On Wednesday?
Arcus Biosciences halts STAR-121 lung cancer trial after futility review while Gilead Science declines option extension.
04-23 03:19
美股大行评级 | 摩根大通上调霸王茶姬至"超配"，目标价上调至16美元；康尼格拉食品遭高盛、瑞银等7家机构下调目标价
今日重点评级关注：Leerink Partners：维持Camp4 Therapeutics"跑赢大市"评级，目标价从8美元升至9美元；韦德布什：维持Arcus Biosciences"跑赢大市"评级，目标价从37美元升至41美元
04-06 16:27
